MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Löffler-Walz, C.
Right arrow Articles by Quast, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Löffler-Walz, C.
Right arrow Articles by Quast, U.

Vol. 61, Issue 2, 407-414, February 2002

Interaction of KATP Channel Modulators with Sulfonylurea Receptor SUR2B: Implication for Tetramer Formation and Allosteric Coupling of Subunits

Cornelia Löffler-Walz, Annette Hambrock, and Ulrich Quast

Department of Pharmacology, Medical Faculty, University of Tübingen, Tübingen, Germany

Sulfonylurea receptors (SURs) are subunits of ATP-sensitive K+ channels (KATP channels); they mediate the channel-closing effect of sulfonylureas such as glibenclamide and the channel-activating effect of KATP channel openers such as the pinacidil analog P1075. We investigated the inhibition by MgATP and P1075 of glibenclamide binding to SUR2B, the SUR subtype in smooth muscle. To increase specific binding, experiments were also performed using SUR2B(Y1206S), a mutant with higher affinity for glibenclamide than for the wild-type (KD = 4 versus 22 nM, respectively) but otherwise exhibiting similar pharmacological properties. In the absence of MgATP, [3H]glibenclamide binding to both SURs was homogenous. MgATP inhibited [3H]glibenclamide binding to both SURs to 25% by reducing the apparent number of glibenclamide binding sites, leaving the affinity unchanged. In the absence of MgATP, P1075 inhibited [3H]glibenclamide binding in a monophasic manner with Ki approx 1 µM. In the presence of MgATP (1 mM), inhibition was biphasic with one Ki value resembling the true affinity of P1075 for SUR2B (2-6 nM) and the other resembling Ki in the absence of MgATP (approx 1 µM). The data show that (1) MgATP induces heterogeneity in the glibenclamide sites; (2) the high-affinity glibenclamide sites remaining with MgATP are linked to two classes of P1075 sites; and (3) P1075 interacts specifically with SUR2B also in the absence of MgATP. The data are discussed with the assumption that SUR2B, expressed alone, forms tetramers; that MgATP induces allosteric interactions between the subunits; and that mixed SUR2B-glibenclamide-P1075 complexes can exist at equilibrium.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. Winkler, D. Stephan, S. Bieger, P. Kuhner, F. Wolff, and U. Quast
Testing the Bipartite Model of the Sulfonylurea Receptor Binding Site: Binding of A-, B-, and A + B-Site Ligands
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 701 - 708.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. Hambrock, T. Kayar, D. Stumpp, and H. Osswald
Effect of Two Amino Acids in TM17 of Sulfonylurea Receptor SUR1 on the Binding of ATP-Sensitive K+ Channel Modulators
Diabetes, December 1, 2004; 53(suppl_3): S128 - S134.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
P. Proks, F. Reimann, N. Green, F. Gribble, and F. Ashcroft
Sulfonylurea Stimulation of Insulin Secretion
Diabetes, December 1, 2002; 51(90003): S368 - 376.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
U. Lange, C. Loffler-Walz, H. C. Englert, A. Hambrock, U. Russ, and U. Quast
The Stereoenantiomers of a Pinacidil Analog Open or Close Cloned ATP-sensitive K+ Channels
J. Biol. Chem., October 18, 2002; 277(43): 40196 - 40205.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. M. K. Hansen, I. T. Christensen, J. B. Hansen, R. D. Carr, F. M. Ashcroft, and P. Wahl
Differential Interactions of Nateglinide and Repaglinide on the Human {beta}-Cell Sulphonylurea Receptor 1
Diabetes, September 1, 2002; 51(9): 2789 - 2795.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics